The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial
Open accessAbstract
BACKGROUND: Interleukin-1 (IL-1) is a key mediator of ischaemic brain injury induced by stroke and subarachnoid haemorrhage (SAH). IL-1 receptor antagonist (IL-1Ra) limits brain injury in experimental stroke and reduces plasma inflammatory mediators associated with poor outcome in ischaemic stroke patients. Intravenous (IV) IL-1Ra crosses the blood-brain barrier (BBB) in patients with SAH, to achieve cerebrospinal fluid (CSF) concentrations that are neuroprotective in rats. METHODS: A small phase II, double-blind, randomised controlled study was carried out across two UK neurosurgical centres with the aim of recruiting 32 patients. Adult patients with aneurysmal SAH, requiring external ventricular drainage (EVD) within 72 hours of ictus, were eligible. Patients were randomised to receive IL-1Ra (500 mg bolus, then a 10 mg/kg/hr infusion for 24 hours) or placebo. Serial samples of CSF and plasma were taken and analysed for inflammatory mediators, with change in CSF IL-6 between 6 and 24 hours as the primary outcome measure. RESULTS: Six patients received IL-1Ra and seven received placebo. Concentrations of IL-6 in CSF and plasma were reduced by one standard deviation in the IL-1Ra group compared to the placebo group, between 6 and 24 hours, as predicted by the power calculation. This did not reach statistical significance (P = 0.08 and P = 0.06, respectively), since recruitment did not reach the target figure of 32. No adverse or serious adverse events reported were attributable to IL-1Ra. CONCLUSIONS: IL-1Ra appears safe in SAH patients. The concentration of IL-6 was lowered to the degree expected, in both CSF and plasma for patients treated with IL-1Ra.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, C. M., Kistler, J. P., & Davis, J. M. (1980) · Neurosurgery · doi:10.1227/00006123-198001000-00001 · Cited by 3,080
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
van Gijn, J., Kerr, R. S., & Rinkel, G. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60153-6 · Cited by 1,677
(1988) · Journal of Neurosurgery · doi:10.3171/jns.1988.68.6.0985 · Cited by 1,196
Pickard, J. D., Murray, G. D., Illingworth, R. D., Shaw, M. D. M., Teasdale, G. M., Foy, P. M., Humphrey, P. R. D., Lang, D. A., Nelson, R. J., Richards, P., et al. (1989) · CRC Press eBooks · doi:10.1136/bmj.298.6674.636 · Cited by 1,144
Interleukin-1 and neuronal injury
Allan, S. M., Tyrrell, P. J., & Rothwell, N. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1664 · Cited by 992
Self-citationMacdonald, R. L., Higashida, R. T., Keller, E., Mayer, S. A., Molyneux, A., Raabe, A., Vajkoczy, P., Wanke, I., Bach, D., Frey, A., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70108-9 · Cited by 644
Salman, R. A., M, W. P. A. N. E. T. H. H. H. A., Davenport, R. J., Lindsay Kenneth, W., & 周立新 (2007) · doi:10.3760/cma.j.issn.1007-9742.2007.02.122 · Cited by 475
Loddick, S. A., & Rothwell, N. J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00017 · Cited by 463
Self-citationA randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients
Emsley, H. C. A. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054882 · Cited by 445
Cited by
Neuroinflammation: friend and foe for ischemic stroke
Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1516-2 · Cited by 1,428
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., Lu, D., Wei, W., Wang, Y., Li, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42286-8 · Cited by 896
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
NF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 630
Metadata
- Authors
- Singh, N., Hopkins, S. J., Hulme, S., Galea, J. P., Hoadley, M., Vail, A., Hutchinson, P. J., Grainger, S., Rothwell, N. J., King, A. T., & Tyrrell, P. J.
- Venue
- Journal of Neuroinflammation
- Published
- 2014-01-03
- Volume
- 11
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2131528206
- Cited by
- 284
- References
- 24
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. https://app.cochat.ai/papers/10.1186/1742-2094-11-1
- The paper
- Singh, N., Hopkins, S. J., Hulme, S., Galea, J. P., Hoadley, M., Vail, A., Hutchinson, P. J., Grainger, S., Rothwell, N. J., King, A. T., & Tyrrell, P. J. (2014). The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. Journal of Neuroinflammation. https://doi.org/10.1186/1742-2094-11-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.